METHYSDx Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$1.05M
- Investors
-
4
METHYSDx General Information
Description
Developer of an innovative diagnostic testing technology designed for cancer monitoring and prognosis. The company develops diagnostic kits based on proprietary methylation signatures and liquid biopsy technology, enabling healthcare professionals to analyze circulating tumor DNA and monitor disease progression in patients with advanced cancers.
Contact Information
Website
www.methysdx.comCorporate Office
- 67 rue Saint Jacques
- 75005 Paris
- France
Corporate Office
- 67 rue Saint Jacques
- 75005 Paris
- France
METHYSDx Timeline
METHYSDx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Equity Crowdfunding | 13-May-2026 | $1.05M | Completed | Generating Revenue | ||
| 6. Early Stage VC | 01-Apr-2026 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | 01-Jan-2025 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Jan-2025 | Completed | Generating Revenue | |||
| 3. Seed Round | 25-Aug-2023 | Completed | Startup | |||
| 2. Accelerator/Incubator | 16-Nov-2022 | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-May-2021 | Completed | Startup |
METHYSDx Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
METHYSDx Patents
METHYSDx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026215463-A1 | Detection of hypermethylated genes for diagnosing or monitoring urothelial cancer | Pending | 11-Apr-2025 | ||
| WO-2026162840-A1 | Detection of hypermethylated genes or genomic regions for diagnosing or monitoring sarcoma | Pending | 03-Feb-2025 | ||
| EP-4735641-A1 | Detection of hypermethylated genes for diagnosing colorectal cancer | Pending | 30-Jun-2023 | ||
| WO-2025003512-A1 | Detection of hypermethylated genes for diagnosing colorectal cancer | Inactive | 30-Jun-2023 | C12Q1/6886 |
METHYSDx Signals
METHYSDx Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Creative Destruction Lab | Accelerator/Incubator | |||
| Neighborhood | Accelerator/Incubator | |||
| Wilco(Paris) | Accelerator/Incubator | |||
| Erganeo | Venture Capital | Minority |
METHYSDx FAQs
-
When was METHYSDx founded?
METHYSDx was founded in 2021.
-
Where is METHYSDx headquartered?
METHYSDx is headquartered in Paris, France.
-
What is the size of METHYSDx?
METHYSDx has 23 total employees.
-
What industry is METHYSDx in?
METHYSDx’s primary industry is Diagnostic Equipment.
-
Is METHYSDx a private or public company?
METHYSDx is a Private company.
-
What is the current valuation of METHYSDx?
The current valuation of METHYSDx is .
-
What is METHYSDx’s current revenue?
The current revenue for METHYSDx is .
-
How much funding has METHYSDx raised over time?
METHYSDx has raised $2.72M.
-
Who are METHYSDx’s investors?
Creative Destruction Lab, Neighborhood, Wilco(Paris), and Erganeo have invested in METHYSDx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process